IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Trial record 1 of 1 for:
NCT02683876
Exploratory Study of Relationships Between Malodor and Urine Metabolomics
This study is ongoing, but not recruiting participants.
Sponsor:
Mebo Research, Inc.
Collaborator:
University of Alberta
Information provided by (Responsible Party):
Mebo Research, Inc.
ClinicalTrials.gov Identifier:
NCT02683876
First received: February 3, 2016
Last updated: July 7, 2017
Last verified: July 2017
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to identify metabolic signatures associated with malodor conditions. The investigators will perform state-of-the art metabolomics tests and bioinformatic data mining to explore if conditions leading to malodor can be screened by metabolomic profiling of urine samples.
| Condition |
|---|
| Nutritional and Metabolic Diseases |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Control Time Perspective: Prospective |
| Official Title: | Metabolomic Profiling of Urine Samples for the Identification of Novel Biomarkers and Mechanisms in the Diagnosis and Management of Malodor Associated With Metabolic Inefficiencies |
Resource links provided by NLM:
Further study details as provided by Mebo Research, Inc.:
Primary Outcome Measures:
- Differences in metabolite concentrations measured by mass spectrometry, comparing urine samples from individuals with malodor issues, and age-matched healthy controls. [ Time Frame: ten months ]The investigators would like to validate if urine metabolomic profiling can be used for identifying key metabolomic signatures associated with malodor
Secondary Outcome Measures:
- Correlations between urine biomarkers and frequency/severity of malodor symptoms (questionnaires) [ Time Frame: one year ]The investigators will comprehensively analyze the ability of metabolite levels to discriminate frequent and severe from non-severe malodor symptoms
| Enrollment: | 54 |
| Actual Study Start Date: | February 2016 |
| Estimated Study Completion Date: | December 2017 |
| Estimated Primary Completion Date: | September 30, 2017 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Subjects with malodor
individuals with self-reported odor issues suspected to be associated with microbial imbalance on or inside the body and inefficient metabolism as evidenced from other laboratory tests
|
|
Healthy control
individuals not complaining of uncontrollable or unpredictable malodor episodes
|
Detailed Description:
In this study, metabolite profiling analysis will be carried out on urine samples of individuals with malodor conditions related to metabolism inefficiencies. Metabolic profiles will be identified using the metabolomics equipment located in the NMR, HPLC and MS facilities of the Metabolomics Innovation Centre (TMIC). Multivariate statistical analyses will be used, as well as other approaches to mine complex data from heterogeneous sources.
Eligibility| Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Study Population
individuals complaining of uncontrollable episodes of malodor suspected to be caused by inefficient body metabolism
Criteria
Inclusion Criteria:
- 18 years or older
- unpredictable and uncontrollable episodes of malodor
- willing and able to ship a urine sample (in the kit provided) by an overnight courier to Edmonton, Alberta, Canada
- good general health
Exclusion Criteria:
- serious medical conditions that require treatment
- conditions that, in the opinion of the investigator, would prevent participation
- under the age of 18
- elect not to participate in the study
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT02683876
Please refer to this study by its ClinicalTrials.gov identifier: NCT02683876
Locations
| United States, Florida | |
| MeBO Research | |
| Miami, Florida, United States, 33175 | |
| Canada, Alberta | |
| The Metabolomics Innovation Centre | |
| Edmonton, Alberta, Canada, T6G 2E9 | |
Sponsors and Collaborators
Mebo Research, Inc.
University of Alberta
Investigators
| Principal Investigator: | David Wishart, PhD | The Metabolomics Innovation Centre (TMIC) |
| Principal Investigator: | Irene Gabashvili, PhD | MeBo Research |
More Information
Additional Information:
Publications:
| Responsible Party: | Mebo Research, Inc. |
| ClinicalTrials.gov Identifier: | NCT02683876 History of Changes |
| Other Study ID Numbers: |
201505010014MEBO |
| Study First Received: | February 3, 2016 |
| Last Updated: | July 7, 2017 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Plan Description: | to prevent risks of re-identification. |
Keywords provided by Mebo Research, Inc.:
|
body odor, malodor, halitosis |
Additional relevant MeSH terms:
|
Metabolic Diseases |
ClinicalTrials.gov processed this record on July 24, 2017